
Opinion|Videos|December 19, 2023
Retrospective Study on Bortezomib Dosing in NDMM
Jens Hillengass, MD, PhD, and the Oncology Brothers discuss a retrospective observational study on real-world bortezomib prescribing patterns and outcomes in newly diagnosed multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
4
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
5

































